Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Enzalutamide in AR-positive Triple-negative Breast Cancer
2013-000698-57Phase 2Unknown
- Sponsor
- Medivation
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in triple-negative breast cancer (TNBC), sponsored by Medivation. Primary endpoint: Clinical benefit rate at >16 weeks. Status: unknown.
02
Drugs
enzalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2013-000698-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000698-57.